Tumors lacking CD24 expression have been found to be more sensitive to CD47 blockers, suggesting that simultaneous targeting of CD24 and CD47 may offer better clinical prospects for treating ovarian cancer [139]. This evidence concerns the gene CD24 and ovarian carcinoma.